cas 1517-69-7|| where to buy (R)-1-Phenylethanol

Product Name:(R)-1-Phenylethanol

IUPAC Name:(1R)-1-phenylethan-1-ol

Packing Unit	Available Stock	Price($)
CM109467-100g	in stock	ŗȃ
CM109467-500g	in stock	ƿŗƿ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1517-69-7 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1517-69-7; Molecular Formula:C8H10O; Melting Point:-; Smiles Code:C[C@@H](O)C1=CC=CC=C1; Density:

: Catalog Number:CM109467; Molecular Weight:122.17; Boiling Point:206.9°C at 760 mmHg; MDL No:MFCD00064263; Storage:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Alcohols; Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.

: Encaleret; New England Journal of Medicine(NEJM) publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1 (ADH1).
Encaleret is an investigational, orally administered small molecule that selectively antagonizes the calcium sensing receptor (CaSR), targeting ADH1 at its source. If approved, encaleret could be the first therapy specifically indicated for the treatment of ADH1.
Encaleret has received fast track designation by the U.S. FDA and orphan drug designation in the United States and the European Union.